Eversept Partners’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Eversept Partners’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,634	Closed	-$470K	–	68
2020 Q2	$470K	Sell	1,634 -690	-30%	-$203K	0.06%	67
2020 Q1	$474K	Hold	2,324	–	–	0.12%	56
2019 Q4	$1.04M	Hold	2,324	–	–	0.18%	63
2019 Q3	$715K	Hold	2,324	–	–	0.22%	49
2019 Q2	$739K	Hold	2,324	–	–	0.21%	50
2019 Q1	$975K	Buy	+2,324	New	+$933K	0.28%	41

Other funds holding EIGR

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Eversept Partners's EIGR Position: Q3 2020 in Review

Eversept Partners sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2020, closing a stake of 1,634 shares — an estimated $470K sold.

Eversept Partners first reported a position in EIGR in Q1 2019 and held it in 6 quarters. The position peaked at $1.04M in Q4 2019. 102 funds tracked by Wall St. Rank hold EIGR as of Q3 2020.

Eversept Partners reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Eversept Partners sold 1,634 Eiger BioPharmaceuticals, Inc. shares in Q3 2020, an estimated $470K.
Eversept Partners first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2019 and held it in 6 quarters.
Eversept Partners's Eiger BioPharmaceuticals, Inc. position peaked at $1.04M in Q4 2019.
102 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2020.

Based on Eversept Partners's 13F filing for Q3 2020, filed 12 Nov 2020.